InsightFinance
Gan & Lee inks third overseas out-licensing deal for its GLP-1 asset with Korea's JW Pharma, worth up to $81M Furthermore, Gan & Lee Pharmaceuticals is developing an oral formulation of Bofanglutide. The GZR18 tablet utilizes SNAC absorption enhancer technology. Phase I data indicated that after two weeks of treatment with a 60mg dose, healthy subjects achieved a mean body weight reduction of 4.16% from baseline.
6min read
Read More 
We help global healthtech companies, investors, and institutions with the right local partners—from distributors and licensees to investment targets and R&D collaborators.
IPO
Cofoe Medical Technology Files for Hong Kong IPO to Accelerate Global Expansion and Smart Health Innovation Cofoe Medical Technology Co., Ltd., China's #2 home-use medical device company with a 2.1% domestic market share and leader in rehabilitation assistive devices (2.4% share), has filed its prospectus for a primary listing on the Hong Kong Stock Exchange. The Changsha-based firm reported RMB 3.39 billion ($468 million) in 2025 revenue (+13.6% YoY) and RMB 370 million net profit (10.9% margin), driven by a strategic shift toward high-margin self-produced products that lifted gross margins from 41.1% in 2023 to 51.7% in 2025. Despite declining R&D spending (down to 2.6% of revenue) and rising sales expenses (34.2% of revenue), Cofoe leverages a portfolio of over 200 product categories, 699 patents, and strong online-direct channels—now 33.4% of revenue. Proceeds from the HKEX listing will fund global expansion into Europe, North America, and Southeast Asia; strategic M&A; AI/IoT-enabled product development; and domestic channel deepening. With China’s home-use medical device market projected to reach RMB 313.1 billion by 2030, Cofoe aims to transform from a domestic leader into a global health-tech brand.
7min read
Read More 
Startups
Photon counting CT battle royale United Imaging has showcased more imaging information from uCT Ultima at its booth this year, combined with unique rendering technology, which indeed elevates imaging and performance to a new level. In terms of commercialization, uCT Ultima has been installed and officially put into clinical use at West China Xiamen Hospital, Sichuan University, and Huaxi Xiamen Hospital. Regarding clinical validation, the on-site staff stated that more than 4,000 clinical scans have been completed in total.
7min read
Read More 
Startups
When Metabolic CT Meets Novel Poly-Amino Acid Contrast Agent: Oscillare and Philips Join Hands to Define a New Paradigm in Imaging Diagnosis On April 10, 2026, addressing industry pain points and clinical needs, Hangzhou Aosaire Biomedical Technology Co., Ltd. and Philips Healthcare officially announced a strategic partnership at the 93rd China International Medical Equipment Fair (CMEF). The collaboration aims to advance the clinical application of novel poly-amino acid contrast agents in metabolic CT. One party is an innovative pioneer in medical imaging contrast agents, while the other is a global leader in CT technology. This alliance marks the emergence of a "device + contrast agent" co-innovation model for the global metabolic CT ecosystem, ushering medical imaging into a new era of precision metabolic imaging. At this CMEF exhibition, the core product of the collaboration between Aosaire and Philips, Bi@POS (bismuth-loaded poly-amino acid contrast agent), garnered significant attention from industry professionals. In terms of physical properties, compared with traditional iodine-based contrast agents, Bi@POS offers greater energy separation, enabling seamless integration with Philips Meta CT for more precise material separation and quantitative analysis. Preclinical data shows that Bi@POS achieves CT contrast imaging efficiency approximately three times higher than iohexol, with a nanoscale size of about 20nm, allowing targeted delivery. More importantly, Bi@POS is metabolized through the hepatobiliary system, making it more suitable for patients with renal insufficiency and effectively avoiding the nephrotoxicity issues associated with traditional iodine-based contrast agents.
7min read
Read More 
Startups
All-out IPO Push! This Respiratory Track Pharma Company Enters a Life-or-Death Battle On April 8, 2026, the SEC's official website disclosed the IPO prospectus of Avalyn Pharma Inc. This Boston-based clinical-stage biopharmaceutical company submitted its listing application to Nasdaq. As an innovative pharmaceutical enterprise specializing in rare respiratory diseases, its IPO is a do-or-die battle for survival, trading nearly nine years of R&D accumulation and continuously expanding losses for the resolution of funding difficulties and the opportunity for product commercialization. In 2017, the global field of respiratory disease treatment stagnated. Idiopathic pulmonary fibrosis (IPF), which predominantly affects the elderly, has a poor prognosis, and oral medications have significant side effects, with about 50% of patients discontinuing treatment within a year due to intolerance. Chronic obstructive pulmonary disease (COPD) treatment still relies on traditional drugs, making it difficult to improve patients' quality of life. The large number of unmet clinical needs presents potential opportunities. In terms of drug therapy, there have been only two specific anti-fibrotic oral medications available over the long term, until the introduction of Namivibeg at the end of 2025. Avalyn was founded in 2011 and renamed in July 2017.
8min read
Read More 
Startups
Fill the Technical Path Gap of Local Similar Products! "RF + Mechanical" Dual-Technology Atrial Septal Puncture System Approved In the first quarter, Huiyang Medical obtained registration certificates for two innovative medical devices, forming China's first RF-cross® Radiofrequency Atrial Septal Puncture System with "Zero Exchange, Mechanical + Radiofrequency Dual Technology, and Compatibility with Adjustable Bending." In 2024, it entered the National "Special Review Channel for Innovative Medical Devices" and has now initiated the commercialization process, offering the potential to provide a safer and more controllable domestically produced solution for cardiac interventional surgeries. Atrial septal puncture is a commonly used technique in left atrial interventional treatments. Taking atrial fibrillation (AF) treatment as an example, the number of AF patients in China is vast and continuously growing, with the volume of AF ablation surgeries constantly rising, driving the market demand growth for core devices such as puncture needles and puncture sheaths used in atrial septal puncture procedures. However, the current clinically prevalent mechanical puncture methods have shortcomings, including high operational difficulty, a steep learning curve for doctors, potential severe complications, challenges in precisely predicting the puncture site, and time-consuming puncture processes.
6min read
Read More 
Startups
From Single-point Tools to Intelligent Foundation: Deepwise Completes Strategic Leap in Medical AI through Scenario-based Solutions At this year's CMEF, AI has permeated every corner of medical devices, with Deepwise completing a transformation from technology-centric to clinically-focused. By reshaping the AI empowerment pathway through scenario-based thinking, it builds AI tailored to specific diseases and around the entire clinical diagnosis and treatment process, offering departments comprehensive solutions—fundamentally different from single-point AIs in the market. At this CMEF, Deepwise launched its multimodal clinical intelligence platform, Deepwise MetAI X, positioned as an all-hospital-level multimodal intelligent hub and digital intelligence foundation. Relying on a "dual-bus" architecture and dual AI engines for "imaging + text," it can centrally manage multimodal imaging data, deeply integrate key processes, form an end-to-end intelligent service system, and reconstruct the operational logic of radiology departments. Its core breakthrough lies in AI-native integration, being both scalable and expandable, providing hospitals with a one-stop intelligent imaging hub.
5min read
Read More 
Startups
$15.725 Billion Four-Deal Spree! Gilead Sciences Not Content Being Just the HIV Leader Gilead Sciences, Not Content as HIV Leader, Shows Strong Ambition in Oncology. On April 9, it secured global development rights for KT-200. The original developer, Kymera, will receive a $45 million milestone payment and is eligible for substantial total payments and tiered royalties. On the 100th day of 2026, Gilead made its fourth move, with a potential total deal value of approximately $15.725 billion, including the acquisition of CAR-T company Arcellx, the merger with Ouro Medicines, and the purchase of Germany's next-generation ADC company Tubulis Technologies. KT-200, the subject of this transaction, is the world’s first oral molecular glue degrader targeting CDK2, which selectively eliminates CDK2, a key driver of tumor growth, offering a more precise, safe, and effective oral treatment option for cancers dependent on CDK2 activity. Preclinical tests have shown strong activity, potential for brain penetration, and good safety.
6min read
Read More Startups
Reaching the Top of "Radiology", Phased Array CT Rewrites the Evolution Path of Ultra-High-End On April 10, 2026, it was reported that *Radiology*, the top international journal in radiology, published a highly anticipated prospective clinical study. The study focused on the clinical performance of using "dual-ring phased array static CT" for diagnosing small pulmonary nodules. The research demonstrated that the dual-ring phased array static CT, independently developed by Beijing Nano-dimensional King Technology Co., Ltd., performed exceptionally well in detecting small nodule lesions. With an ultra-fine slice thickness of 0.165mm and tens of millions of pixel-level imaging, the device can clearly capture pathological details of terminal bronchioles at levels 9 to 12 and small nodule lesions. The achievement of extremely high-resolution imaging is due to the reconstruction of the imaging logic. The dual-ring phased array static CT abandons the principle of "mechanical rotation" imaging and instead adopts "optical rotation" imaging, completing 360° data acquisition through sequential pulse exposure from numerous X-ray sources on a ring gantry, completely eliminating the centrifugal force limitations and artifacts caused by mechanical rotation. In the study, the phased array CT was compared with globally leading high-end spiral CTs. The results showed that while traditional CTs could only visualize bronchi up to level 7, the phased array CT could display terminal bronchioles at levels 9 to 12; among 11 pulmonary structures, the visibility scores for 8 structures significantly surpassed those of traditional devices.
4min read
Read More 
Finance
Oricell Therapeutics closes $110 million Pre-IPO financing to accelerate global development of solid tumor CAR-T therapies As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo(Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race.
7min read
Read More 
Finance
NorrDia Medical completes new financing round exceeding RMB 100 million to accelerate the development of a global full-category blood purification platform The significant scale increase of this current round signals that NorrDia Medical has formally transitioned from a single-line focus on acute critical care into a new stage of platform-based development, characterized by the synergistic advancement of both acute and chronic disease portfolios, driven by a dual-engine approach in both domestic and international markets.
3min read
Read More
We provide comprehensive advisory services to global healthtech companies, international investors, and institutions seeking to understand, assess, and enter the complex Chinese healthcare market.
2025 Innovative Drug & Supply Chain Innovation White Paper
We stand today at a pivotal moment in the era of biopharmaceuticals. Accelerating global health demands, deepening convergence of cutting-edge technologies, and dramatic restructuring of the industrial landscape are shaping our collective future—and China is integrating into this wave of innovation with unprecedented momentum. In 2025, following a period of rational consolidation, China's innovative drug and supply chain industry has entered a phase of value reorientation and structural reinvention. This year has thus become a defining chapter in which Chinese innovation repositions itself within the global healthcare ecosystem.
2025 Digital Health Innovation White Paper
In 2025, the digital health industry demonstrated vigorous growth driven by technological innovation and robust capital support. Breakthroughs in two core fields—artificial intelligence and brain-computer interfaces—have been particularly significant, injecting strong momentum into the sector's development.
2025 Healthcare AI Industry Report: Exploring Value Measurement and Payment to Overcome the Challenges of Medical AI
From deep learning to large language models, the widespread adoption of AI has already transformed the revenue structures of many leading companies, becoming a key driver of innovation and productivity. Yet, the medical field appears largely disconnected from this wave. Despite multiple waves of underlying technological change and thousands of enterprises striving tirelessly, none have managed to achieve large-scale profitability. Does the healthcare sector truly have a demand for AI? Is the bottleneck in data, computing power, or algorithms? What can we expect in the short and long term? And where does the key to commercial breakthrough lie?
In Depth
New drug priced at 3,000 RMB per box sells out quickly; are young "wind cluster" entrepreneurs making a profitable business? But in practice, patients often feel that there are no effective drugs available. The progression of the disease and the ineffectiveness of the drugs tend to exceed expectations, while the complexity and side effects of upgraded drugs increase sharply, with unsatisfactory efficacy. About half of the patients find that standard-dose second-generation antihistamines are directly ineffective. Of these, nearly half also find no effect after increasing the dose or combining antihistamines for a year, and more than 40% of patients still have not achieved effective control after one year.
9min read
Read More 
Policy
How Does the 14 Measures Leverage Health Insurance to Solve the Problem of Difficult Access to Medical Care: From "Unwilling to Go" to "Happy to Stay" at the Grassroots? For a long time, China's grassroots medical and health institutions have faced multiple challenges. To address this, the National Healthcare Security Administration and two other departments issued the "Guiding Opinions on Medical Insurance Support for the Development of Grassroots Medical and Health Services," proposing 14 measures. These measures focus on solving the difficulties in grassroots medical treatment and healthcare security for the public, including ensuring stable medical insurance fund support at the grassroots level, improving the three-tier drug use linkage mechanism, clarifying charging codes and medical insurance payment support for services like home visits, and promoting the "sign and fulfill" approach for family doctors. To make medical expense reimbursement more beneficial and drug procurement more convenient for the grassroots population, the "Opinions" also propose optimizing regional total medical insurance fund management, with an appropriate tilt of annual additional funds towards the grassroots level, and implementing "total payment" for closely-knit county-level medical consortia, providing grassroots institutions with stable financial expectations and changing grassroots behavioral orientation.
6min read
Read More In Depth
An Innovative High-Priced Skin Drug Sells Like Hotcakes on E-Commerce Platforms! The Potential of the Dermatological Drug Market is Huge. In March 2026, CMS launched its innovative dermatological drug, **Prolutex® Ruxolitinib Phosphate Cream**, which set a sales record for self-paid innovative drugs in China upon its market debut. On the first day of its launch on Jingdong Health, over 5,000 units were sold, and within a month, sales exceeded 10,000 units. The explosive popularity stemmed from CMS's transformation. In 2018, CMS announced its transition to an innovative pharmaceutical company, and in 2022, it partnered with Incyte Corporation to acquire the rights to Ruxolitinib Cream in Greater China and Southeast Asia. The success of Ruxolitinib Phosphate Cream as a blockbuster product lies in its precise selection. As a topical targeted JAK inhibitor, it accurately blocks abnormal immune signaling, reduces the area of vitiligo lesions, restores skin color, and demonstrates good tolerability. After 24 weeks of treatment, the F-VASI75 response rate reached 49.5%. It also gained recognition in the *Chinese Expert Consensus on Vitiligo Diagnosis and Treatment (2024 Edition)*.
8min read
Read More 
In Depth
Is Medical AGI Coming? Can It Help Humans Live to 120? By the end of the "14th Five-Year Plan," China's average life expectancy will rise to over 79 years, and the "15th Five-Year Plan" outline proposes to increase the average life expectancy to 80 years over the next five years. Advances in medical technology are a direct driving force for extending life expectancy. In a dialogue between Wang Shirui, founder of Future Doctor, and Kevin Kelly, it was predicted that medical AGI might extend human lifespan to 120 years. Artificial General Intelligence (AGI) is the ultimate goal of AI development, but its realization faces two major challenges: the level of intelligence and human-like consciousness, which are fraught with uncertainty. Wang Shirui believes that medical AGI has clear objectives and iterative paths and will be achieved before general AGI. It possesses the professional personality of doctors, adheres to medical ethics, can integrate into clinical scenarios, and self-iterate. The current healthcare industry faces pain points such as scarce high-quality resources and insufficient capacity for diagnosing and treating complex diseases. Medical AGI could be key to solving these problems. The high level of societal participation in AI and favorable national policies have created a favorable environment for the technological exploration and application of medical AGI.
10min read
Read More 
Expert Interview
After billions of dollars, how will China-produced IL-4Rα play its cards? Clinical results show that, compared with conventional therapy and immunotherapy, Stapokibart, as a biologic, directly targets the core drivers of type 2 inflammation (IL-4 and IL-13). Provides a new precise treatment pathway for patients with moderate to severe allergic rhinitis. By targeting allergic rhinitis, Stapokibart has avoided direct competition with Dupilumab and found a differentiated market for itself.
8min read
Read More 
Policy
China's National Healthcare Security Administration Implements New Regulations: Precisely Cracking Down on Inducement-based Insurance Fraud with "Free Rice, Flour, and Oil," Solving DRG/DIP Supervision Challenges On April 1, 2026, the seventh order of the National Healthcare Security Administration, "Detailed Rules for the Implementation of the Regulations on the Supervision and Administration of the Use of Medical Security Funds," will officially come into effect. The "Detailed Rules" consist of five chapters and 46 articles, providing stronger legal basis for fund supervision. Since the implementation of the "Regulations" nearly five years ago, the healthcare security departments have recovered approximately 120 billion yuan of medical insurance funds, with intelligent supervision recovering 9.5 billion yuan in fund losses, but some problems still remain. The "Detailed Rules" smooth out the "last mile" of implementing the "Regulations," precisely cracking down on fraud and deception related to insurance claims. It focuses on tackling fraudulent practices such as "vehicle pick-up and drop-off, fee reduction or exemption, and giving away rice, flour, and oil." Clear regulations are provided for fraudulent behaviors by different entities, including designated medical institutions, individuals, drug traffickers, and insured persons. It particularly emphasizes combating the resale of "recycled drugs," stating that drug traceability codes can serve as evidence for law enforcement. Additionally, it elaborates on scenarios of individual fraud.
5min read
Read More 
In Depth
OpenEvidence is by no means the endgame for domestically produced medical AI in China. U.S. Tech Companies Continue to Break Records in Healthcare AI Funding: Abridge Raises $300 Million, Tala Health Secures $100 Million Super Seed Round, Open Evidence Receives $250 Million from Thrive Capital and DST Global; Financial Advisors Not Disclosed. Funds to Be Used for Business Expansion, Valuation Growth, etc. Abridge Focuses on AI-Powered Clinical Documentation Automation Platform, Addressing the Pain Points of Physicians in Medical Record Keeping; In China, Companies Such as Fuxin Innovation Have Similar Technologies with Slightly Superior Capabilities. Tala Health Concentrates on Full-Process Healthcare Navigation, Its Platform Covers the Entire Patient Journey from Initial Diagnosis to Recovery; In China, Companies Like WeDoctor Emphasize Full-Process Medical Coordination and Chronic Disease Closed-Loop Management. The Development of China’s Healthcare IT Companies Remains Lackluster, With Winning Health and B-Soft Experiencing Losses and Declining Market Value; Many Startups Seek to "Localize" the U.S. Model for Quick Monetization.
8min read
Read More
We provide international health innovators with strategic visibility, key connections, and deep market insights in China through a full suite of engagement services.
Startups
Photon counting CT battle royale United Imaging has showcased more imaging information from uCT Ultima at its booth this year, combined with unique rendering technology, which indeed elevates imaging and performance to a new level. In terms of commercialization, uCT Ultima has been installed and officially put into clinical use at West China Xiamen Hospital, Sichuan University, and Huaxi Xiamen Hospital. Regarding clinical validation, the on-site staff stated that more than 4,000 clinical scans have been completed in total.
7min read
Read More Startups
$15.725 Billion Four-Deal Spree! Gilead Sciences Not Content Being Just the HIV Leader Gilead Sciences, Not Content as HIV Leader, Shows Strong Ambition in Oncology. On April 9, it secured global development rights for KT-200. The original developer, Kymera, will receive a $45 million milestone payment and is eligible for substantial total payments and tiered royalties. On the 100th day of 2026, Gilead made its fourth move, with a potential total deal value of approximately $15.725 billion, including the acquisition of CAR-T company Arcellx, the merger with Ouro Medicines, and the purchase of Germany's next-generation ADC company Tubulis Technologies. KT-200, the subject of this transaction, is the world’s first oral molecular glue degrader targeting CDK2, which selectively eliminates CDK2, a key driver of tumor growth, offering a more precise, safe, and effective oral treatment option for cancers dependent on CDK2 activity. Preclinical tests have shown strong activity, potential for brain penetration, and good safety.
6min read
Read More In Depth
An Innovative High-Priced Skin Drug Sells Like Hotcakes on E-Commerce Platforms! The Potential of the Dermatological Drug Market is Huge. In March 2026, CMS launched its innovative dermatological drug, **Prolutex® Ruxolitinib Phosphate Cream**, which set a sales record for self-paid innovative drugs in China upon its market debut. On the first day of its launch on Jingdong Health, over 5,000 units were sold, and within a month, sales exceeded 10,000 units. The explosive popularity stemmed from CMS's transformation. In 2018, CMS announced its transition to an innovative pharmaceutical company, and in 2022, it partnered with Incyte Corporation to acquire the rights to Ruxolitinib Cream in Greater China and Southeast Asia. The success of Ruxolitinib Phosphate Cream as a blockbuster product lies in its precise selection. As a topical targeted JAK inhibitor, it accurately blocks abnormal immune signaling, reduces the area of vitiligo lesions, restores skin color, and demonstrates good tolerability. After 24 weeks of treatment, the F-VASI75 response rate reached 49.5%. It also gained recognition in the *Chinese Expert Consensus on Vitiligo Diagnosis and Treatment (2024 Edition)*.
8min read
Read More 
InnovationMNC China LensIn DepthInsight
2026’s hottest drug asset: with limited clinical data, are pan-KRAS inhibitors overheated? An unavoidable issue is that the clinical application of pan-KRAS inhibitors still faces inherent technical challenges. For example, achieving high selectivity for mutant KRAS over wild-type KRAS and other RAS subtypes to minimize off-tumor toxicity remains difficult. Additionally, the short half-life of existing pan-KRAS inhibitors and the unclear mechanisms of resistance also limit their widespread clinical use to some extent.
8min read
Read More 
InsightFinance
Keymed nets $250M upfront as Gilead acquires Ouro in $2.2B deal, marking China's largest NewCo payout Pursuant to the merger agreement, as a shareholder of Ouro Medicines, Keymed Biosciences will receive approximately $250 million in upfront payment upon completion of the transaction, along with milestone payments of up to approximately $70 million, resulting in total consideration of approximately $320 million. Concurrently, the tiered sales royalties for CM336/OM336 will be fulfilled by Gilead.
7min read
Read More 
InsightInnovation
After the GLP-1 combination drug, does Hengrui have three more "Ace" cards up its sleeve? Recently, Hengrui Pharma announced that the New Drug Application (NDA) for its independently developed Shudi Insulin Noiiglutide Injection (HR17031) has been formally accepted by the National Medical Products Administration (NMPA). However, the acceptance of this product appears to signal the beginning of a defensive battle rather than a charge forward.
7min read
Read More 
MNC China Lens
Rolling out the $15B bet: AstraZeneca unveils cell therapy and RDC hubs in China Meanwhile, total revenue from the China region in 2025 reached USD 6.654 billion, a 4% increase year-over-year. Although this growth rate slowed from 9% in 2024, China's revenue still accounted for 43.5% of total revenue from emerging markets, positioning it as an indispensable strategic pillar in AstraZeneca's global footprint.
6min read
Read More 
Startups
Mindray's Entrepreneurial Roots, Overseas Market Holds Up Half the Sky: MEDCAPTAIN's Journey to Conquer the Hong Kong Stock Market In March 2026, Shenzhen MEDCAPTAIN MEDICAL TECHNOLOGY CO., LTD. filed for listing on the Hong Kong Stock Exchange, jointly sponsored by Morgan Stanley and Huatai International. MEDCAPTAIN's products have entered nine out of ten tertiary hospitals in China, covering over 6,000 hospitals, and are exported to more than 140 countries worldwide. The company holds three major business matrices: life support, minimally invasive intervention, and in vitro diagnostics, with over 300 products forming a synergistic effect. The company’s team is considered the "golden veteran group" in the medical industry. Founder Liu Jie is a veteran of Mindray, having participated throughout Mindray’s globalization process, while partner Zhong Yaoqi specializes in international marketing and strategic mergers and acquisitions. Among the seven senior executives, five have work experience at Mindray Medical. This experienced team enabled MEDCAPTAIN to target the high-end market from the start, avoiding low-end competition and cheap contract manufacturing, focusing instead on technology and quality. Since 2016, MEDCAPTAIN has completed 10 rounds of financing, raising a total of 2.259 billion yuan, with Hillhouse Capital being the largest institutional shareholder, holding over 20% of shares.
7min read
Read More 
In Depth
Will a New $54 Billion Diabetes Leader Soon Emerge? MiniMed, the diabetes business spun off from Medtronic, has filed its prospectus, planning to raise $784 million with a potential valuation exceeding 54 billion yuan. Founded by Alfred E. Mann in 1983, MiniMed has launched numerous industry-first products and was acquired by Medtronic in 2001. After joining Medtronic, MiniMed continued to innovate, releasing several groundbreaking products that solidified Medtronic’s leading position in the diabetes sector. In mid-2022, Medtronic announced the spin-off of its diabetes business. On one hand, MiniMed is the smallest business unit within Medtronic, contributing a low percentage of revenue, with a business model significantly different from other divisions, making it difficult to achieve synergies and leaving it at a disadvantage in internal resource allocation. On the other hand, the diabetes technology market holds immense potential, and MiniMed has achieved growth rates exceeding double digits for multiple consecutive quarters, making it the fastest-growing division within Medtronic. Against this backdrop, Medtronic decided to spin off MiniMed.
9min read
Read More 
MNC China LensFinance
Sino Biopharm and Sanofi reach exclusive global licensing agreement for rovadicitinib, with total transaction value up to $1.53 billion As a first-in-class drug independently developed by CTTQ Pharma, Rovadicitinib is the world's first dual JAK/ROCK inhibitor. Through synergistic action on two pathways, it achieves dual pharmacological effects of anti-inflammation and anti-fibrosis, precisely targeting the core pathological mechanisms of diseases such as myeloproliferative neoplasms and transplant rejection.
4min read
Read More